BackGreat Novel Therapeutics Biotech & Medicals Overview
Great Novel Therapeutics Biotech & Medicals

Great Novel Therapeutics Biotech & Medicals P/E Ratio

Latest P/E ratio for Great Novel Therapeutics Biotech & Medicals: -23.58 — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

P/E Ratio

-23.58

P/E Ratio

-23.58

The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.

P/E Ratio (Comparison Companies)

Loading

P/E Ratio History

Loading

P/E Ratio Comparison

Loading

Great Novel Therapeutics Biotech & Medicals (7427.TWO) FAQ

As of the most recent data, 7427.TWO shows a P/E ratio of -23.58. That is below the Healthcare sector average of 21.65. Scroll down for historical charts and peer comparison views.

The Healthcare sector average P/E ratio is about 21.65. Great Novel Therapeutics Biotech & Medicals is at -23.58, which is lower that average. That is roughly 208.9% below the sector mean. Use the comparison chart on this page to see how 7427.TWO stacks up against individual peers as well.

Investors watch 7427.TWO's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Great Novel Therapeutics Biotech & Medicals's latest reading is -23.58. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.

Besides this p/e ratio page, Stockcircle has Great Novel Therapeutics Biotech & Medicals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -23.58) with ownership activity and broader fundamentals.

The Healthcare average P/E ratio is about 21.65, while 7427.TWO is at -23.58. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.